FindTrial
Sign In

Comparison of the curative effect of stellate ganglion block in the treatment of insomnia and primary insomnia after novel coronavirus infection

Comparison of the curative effect of stellate ganglion block in the treatment of insomnia and primary insomnia after novel coronavirus infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101078
Enrollment
Unknown
Registered
2025-04-18
Start date
2023-10-10
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Insomniacs after novel coronavirus infection:Stellate ganglion block
Patients with primary insomnia:Stellate ganglion block

Sponsors

The Second Affiliated Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age 18 - 64 years old, BMI 18 - 30 kg/m^2, insomnia symptoms last for >=3 months; meet the diagnostic criteria for insomnia; Group A is insomnia after positive nucleic acid test for COVID-19, and Group B is primary insomnia and excludes insomnia caused by other primary diseases.

Exclusion criteria

Exclusion criteria: Merged neurological diseases such as stroke and chronic pain, coagulation disorders, and somatic symptom disorders (score of Chinese version of Somatic Symptom Self-Rating Scale > 36 points).

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index;Insomnia severity index;Hamilton Anxiety Scale score;Hamilton Depression Rating Scale score;Autonomic nerve bias;—

Countries

China

Contacts

Public ContactWang Yaoyao

The Second Affiliated Hospital of Shandong First Medical University

469238908@qq.com+86 152 1538 6606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026